{"id":10517,"date":"2023-12-21T00:12:00","date_gmt":"2023-12-20T16:12:00","guid":{"rendered":"https:\/\/flcube.com\/?p=10517"},"modified":"2024-10-31T00:15:50","modified_gmt":"2024-10-30T16:15:50","slug":"3sbio-partners-with-hq-pharma-to-develop-and-commercialize-eltrombopag-olamine-dry-suspension","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=10517","title":{"rendered":"3SBio Partners with HQ Pharma to Develop and Commercialize Eltrombopag Olamine Dry Suspension"},"content":{"rendered":"\n

3SBio Inc., (HKG: 1530<\/a>), a leading biopharmaceutical company based in China, has entered into a strategic partnership with domestic firm HQ Pharma to collaborate on the technical development and commercialization of HQ Pharma’s in-house developed eltrombopag olamine dry suspension. The financial details of the agreement have not been disclosed.<\/p>\n\n\n\n

Eltrombopag olamine is recognized as the world’s first oral small molecule thrombopoietin (TPO) receptor agonist (TPO-RA), capable of engaging with the transmembrane domain of human TPO receptors to initiate signal transduction reactions. This interaction stimulates the proliferation and differentiation of bone marrow megakaryocytes, promoting platelet production and release. Novartis\u2019s Revolade, the originator product, was first approved in the US in 2008 and later in China in 2018 for the treatment of chronic immune (idiopathic) thrombocytopenia (ITP) in adults and children aged six and above unresponsive to glucocorticoids and immunoglobulins, aiming to increase platelet count and reduce or prevent bleeding.<\/p>\n\n\n\n

HQ Pharma\u2019s dry suspension dosage form marks the first of its kind in China to be filed for marketing, targeting ITP and severe aplastic anemia (SAA). This innovative product avoids dental caries, boasts improved palatability, and can significantly enhance patient compliance. Its convenience in dosage adjustment and precise administration makes it particularly suitable for children, the elderly, and patients with swallowing difficulties.- Fineline.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

3SBio Inc., (HKG: 1530), a leading biopharmaceutical company based in China, has entered into a…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[116,30,1061,1790],"class_list":["post-10517","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-3sbio","tag-biotech","tag-hkg-1530","tag-hq-pharma"],"yoast_head":"\n3SBio Partners with HQ Pharma to Develop and Commercialize Eltrombopag Olamine Dry Suspension - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"3SBio Inc., (HKG: 1530), a leading biopharmaceutical company based in China, has entered into a strategic partnership with domestic firm HQ Pharma to collaborate on the technical development and commercialization of HQ Pharma's in-house developed eltrombopag olamine dry suspension. The financial details of the agreement have not been disclosed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=10517\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"3SBio Partners with HQ Pharma to Develop and Commercialize Eltrombopag Olamine Dry Suspension\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=10517\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-20T16:12:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-30T16:15:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10517#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10517\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"3SBio Partners with HQ Pharma to Develop and Commercialize Eltrombopag Olamine Dry Suspension\",\"datePublished\":\"2023-12-20T16:12:00+00:00\",\"dateModified\":\"2024-10-30T16:15:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10517\"},\"wordCount\":227,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"3SBio\",\"Biotech\",\"HKG: 1530\",\"HQ Pharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10517#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10517\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=10517\",\"name\":\"3SBio Partners with HQ Pharma to Develop and Commercialize Eltrombopag Olamine Dry Suspension - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-12-20T16:12:00+00:00\",\"dateModified\":\"2024-10-30T16:15:50+00:00\",\"description\":\"3SBio Inc., (HKG: 1530), a leading biopharmaceutical company based in China, has entered into a strategic partnership with domestic firm HQ Pharma to collaborate on the technical development and commercialization of HQ Pharma's in-house developed eltrombopag olamine dry suspension. The financial details of the agreement have not been disclosed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10517#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10517\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10517#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"3SBio Partners with HQ Pharma to Develop and Commercialize Eltrombopag Olamine Dry Suspension\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"3SBio Partners with HQ Pharma to Develop and Commercialize Eltrombopag Olamine Dry Suspension - Insight, China's Pharmaceutical Industry","description":"3SBio Inc., (HKG: 1530), a leading biopharmaceutical company based in China, has entered into a strategic partnership with domestic firm HQ Pharma to collaborate on the technical development and commercialization of HQ Pharma's in-house developed eltrombopag olamine dry suspension. The financial details of the agreement have not been disclosed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=10517","og_locale":"en_US","og_type":"article","og_title":"3SBio Partners with HQ Pharma to Develop and Commercialize Eltrombopag Olamine Dry Suspension","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=10517","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-12-20T16:12:00+00:00","article_modified_time":"2024-10-30T16:15:50+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=10517#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=10517"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"3SBio Partners with HQ Pharma to Develop and Commercialize Eltrombopag Olamine Dry Suspension","datePublished":"2023-12-20T16:12:00+00:00","dateModified":"2024-10-30T16:15:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=10517"},"wordCount":227,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["3SBio","Biotech","HKG: 1530","HQ Pharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=10517#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=10517","url":"https:\/\/flcube.com\/?p=10517","name":"3SBio Partners with HQ Pharma to Develop and Commercialize Eltrombopag Olamine Dry Suspension - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-12-20T16:12:00+00:00","dateModified":"2024-10-30T16:15:50+00:00","description":"3SBio Inc., (HKG: 1530), a leading biopharmaceutical company based in China, has entered into a strategic partnership with domestic firm HQ Pharma to collaborate on the technical development and commercialization of HQ Pharma's in-house developed eltrombopag olamine dry suspension. The financial details of the agreement have not been disclosed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=10517#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=10517"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=10517#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"3SBio Partners with HQ Pharma to Develop and Commercialize Eltrombopag Olamine Dry Suspension"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10517","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10517"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10517\/revisions"}],"predecessor-version":[{"id":10518,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10517\/revisions\/10518"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10517"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10517"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10517"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}